Phenotypic ratio of serum amyloid in pre- and type 2 diabetes
A technology for prediabetes, type 2 diabetes
Inactive Publication Date: 2012-05-30
INTRINSIC BIOPROBES
View PDF1 Cites 1 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Although long used as a biomarker of adequacy of a patient's diabetes treatment, previous conflicting data have hampered the use of HbA1C in diabetes determination
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment
[0041] Analysis of the phenotypic ratio of serum amyloid A in human plasma
[0042] An exemplary embodiment of the present invention is to measure the SAA phenotype ratio and use it as a biomarker to distinguish clinically determined sample groups. This exemplary embodiment was analyzed using the mass spectrometry immunoassay (MSIA) technique.
[0043] In this example, a human citrate plasma sample obtained from a patient newly diagnosed with NGT, IGT, or DM was analyzed. 237 plasma samples were obtained from NGT individuals, 98 plasma samples were obtained from IGT patients, and 25 plasma samples were obtained from DM patients, all of which were analyzed in the same way.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The present invention is directed to diagnosing, determining, and / or monitoring type 2 diabetes, pre-diabetes, insulin resistance, and their related conditions by detecting levels and modulations of Serum amyloid A protein (SAA), SAA variants and / or the phenotypic ratio of SAA. The present invention is also directed to methods for identifying and evaluating therapeutic treatments for type 2 diabetes, pre-diabetes, insulin resistance, and their related conditions by monitoring SAA, SAA variants, and / or the phenotypic ration of SAA.
Description
Technical field [0001] The present invention relates to a method for measuring, diagnosing and / or evaluating prediabetes, type 2 diabetes, insulin resistance and related disorders by detecting the level and adjustment of the phenotype ratio of serum amyloid A (SAA). The present invention also relates to methods for screening molecules that modulate such ratios, and their use in treating and / or improving symptoms related to prediabetes, type 2 diabetes, insulin resistance and related disorders. Background of the invention [0002] Type 2 diabetes (also known as type 2 diabetes, non-insulin dependent diabetes or adult-onset diabetes) is a metabolic disease characterized by hyperglycemia. This condition is caused by a lack of insulin produced by the body or by the body's cells producing insulin resistance (insulin resistance). Since insulin is an essential substance for absorbing glucose from the blood, the disorder of insulin homeostasis eventually leads to loss of blood sugar con...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/16
CPCG01N2800/042G01N33/6893G01N2333/4709
Inventor U·A·基尔南D·内代利科维
Owner INTRINSIC BIOPROBES

